Dr. Davis leads the Analytics organization at Karius, a life sciences company focused on generating genomic insights for infectious diseases with a non-invasive blood test that helps clinicians make rapid treatment decisions. By mapping each patient’s microbial landscape from a single blood draw, Karius moves closer to a vision of a world where infectious disease is no longer a major threat to human health. Three analytics teams, Assay Development Analytics, Computational Biology, and Computational Biomarker Discovery, execute on the vision by delivering the analytical blueprint to create an AI-driven infectious disease diagnostic test that is used by physician’s to detect over 1000 pathogens (e.g., bacteria, viruses, mold and fungi). Prior to Karius, Dr. Davis was the Global Head of Bioinformatics and Computational Biology at AbbVie, where he worked for 7 years. Before moving into pharma and biotech, he was a tenured professor at University of Missouri School of Medicine.
FAIRway to Collaborate: Enabling Future Success
As data complexity and generation grows, the ability to recycle data beyond its immediate consumption has become increasingly challenging, both within and outside organizations. Initially, efforts to rectify this were borne by academics seeking to reuse data from publications, while more recently corporations recognized their role in data stewardship. To some, data collection and acquisition may be seen as a short-term effort with a defined focus. In the recent past, business leaders in pharma and biotech tended to think of data as means to an end, typically to support an IND, NDA, or IVD. Realizing that the data may be nearly as valuable for secondary use initially sparked a mostly IT-centric effort in many organizations to build data warehouses, lakes, etc. While necessary, they are not sufficient for success in “upcycling” data. This talk focuses on why those who do this well will have a sustained advantage in the marketplace.